| Serial Number | 90046614 |
| Word Mark | CAPSIDA BIOTHERAPEUTICS |
| Filing Date | Friday, July 10, 2020 |
| Status | 731 - SECOND EXTENSION - GRANTED |
| Status Date | Monday, March 4, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 7, 2023 |
| Goods and Services | Biomanufacturing, namely, manufacturing of pharmaceuticals using biological organisms in the manufacturing process to order and/or specification of others; providing technical information in the field of pharmaceutical manufacturing; custom manufacture of pharmaceuticals; manufacture of nano scale material to the order and specification of others for use in the manufacture of other goods; manufacturing of pharmaceutical preparations for use in gene therapy to the order and specification of others; manufacturing of pharmaceutical preparations for use in gene delivery technology to the order and specification of others; manufacturing of pharmaceutical preparations for use in the treatment of gene therapy treatable diseases to the order and specification of others; manufacturing of pharmaceutical preparations for the treatment of disorders of the central nervous system to the order and specification of others; manufacturing of pharmaceutical preparations for the treatment of cancer to the order and specification of others; manufacture of pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous system and cancer to the order and specification of others; custom manufacturing of biochemical reagents, namely, synthesis for others of clinical medical reagents for use in gene therapy |
| Goods and Services | Pharmaceutical preparations for use in gene therapy; pharmaceutical preparations for use in gene delivery technology for use in the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; pharmaceutical preparations for use in the treatment of gene therapy treatable diseases for use in the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; gene therapy and prophylaxis products, namely, gene transfer, regulation, modulation and delivery pharmaceutical preparations for the treatment of genetic diseases and disorders; pharmaceutical preparations for the treatment of disorders of the central nervous system; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations that facilitate administration of other pharmaceutical preparations into the brain for enhanced treatment of disorders of the central nervous system and cancer, in the nature of drug delivery agents consisting of viral capsids that facilitate the delivery of the preparations; pre-filled syringes and vials containing pharmaceutical preparations for the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders and complications associated therewith |
| Pseudo Mark | CAPSIDA BIO THERAPEUTICS |
| Goods and Services | Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, ribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences; Chemical and biochemical products for use in gene delivery technology namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, ribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences for development of therapeutics and the treatment of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders |
| Goods and Services | Medical treatment of genetic diseases and disorders through use of gene therapy; Medical services, in the nature of gene therapy, in the field of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, and urological, diseases and disorders; Providing patient support services relating to the treatment of medical disorders, namely, providing online medical information in the field of pharmaceutical preparations for treatment of various diseases and providing medical consultancy and advisory services, in the field of gene therapy, via a global computer network; Providing health and medical information about medical disorders, namely information pertaining to gene therapy; Information services, namely, providing medical information pertaining to gene therapy to patients; Providing patient support services relating to cancer and cancer treatment in the nature of an internet-based database of patient medical information where patients can inquire about medical issues and procedures from other patients and can relay information about their medical experiences for support and community; Providing information services, namely, providing medical care consultancy and advisory services pertaining to gene therapy via a global computer network in the field of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, and urological, diseases and disorders; Providing medical information services relating to treatment of medical disorders, namely, providing medical information pertaining to gene therapy to patients and families of patients in the field of administering medication, and patient medical information where patients can inquire about medical issues and procedures pertaining to gene therapy from medical personnel; None of the foregoing related to the fields of disease infection control, disease management, or disease risk |
| Disclaimer with Predetermined Text | "BIOTHERAPEUTICS" |
| Goods and Services | Pharmaceutical research and development in the field of gene therapy; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; custom design and development of biochemical reagents, namely for use in the synthesis for others of clinical medical reagents for use in gene therapy; development of pharmaceutical preparations for use in gene therapy and gene delivery technology; development of products being genetic therapies; scientific research in the field of genetic engineering, biotechnology research services, and research and development of new products in the field of gene therapeutics and research tools; research and development in the biotechnology field; scientific and medical research and development in the field of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders and complications associated therewith; scientific research and product development services for others in the pharmaceutical, biotechnology, medical and agriculture fields; testing, inspection, research, or development of pharmaceutical preparations for gene therapy and gene delivery technology; biomedical research and development, scientific research and development, pharmaceutical research and development and product development services in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies, gene delivery technologies, and effectors to regulate, modulate, and characterize disease states; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and product delivery development of biochemical assays; biomedical research and development, scientific research and development, pharmaceutical research and development and product development in the fields of autoimmune, cancer, cardiovascular, central nervous system, diabetic, dermatological, endocrine, fungal, gastrointestinal, hematologic, hepatological, immunological, infectious, inflammatory, liver, menopausal, metabolic, musculoskeletal, neurological, ophthalmologic, orthopedic, pain, peripheral nervous system, psychiatric, respiratory, renal, urogenital, urological, and viral diseases and disorders; medical services, namely, scientific research in the fields of genetic engineering and gene therapy services; medical services, namely, scientific research in the nature of gene therapy design and delivery services in the field of genetic diseases and disorders |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 6, 2020 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 6, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 6, 2020 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 6, 2020 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, August 6, 2020 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | CAPSIDA BIOTHERAPEUTICS, INC. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Thousand Oaks, CA 91320 |
| Party Name | CAPSIDA BIOTHERAPEUTICS, INC. |
| Party Type | 11 - New Owner Before Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Thousand Oaks, CA 91320 |
| Party Name | Capsida, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Westlake Village, CA 91361 |
| Event Date | Event Description |
| Tuesday, March 5, 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, March 4, 2024 | SOU EXTENSION 2 GRANTED |
| Monday, March 4, 2024 | SOU EXTENSION 2 FILED |
| Monday, March 4, 2024 | SOU TEAS EXTENSION RECEIVED |
| Friday, September 29, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Wednesday, September 27, 2023 | SOU EXTENSION 1 GRANTED |
| Wednesday, September 27, 2023 | SOU EXTENSION 1 FILED |
| Wednesday, September 27, 2023 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, April 4, 2023 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, February 7, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, February 7, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, January 18, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, January 5, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, December 21, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, December 21, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, December 21, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, June 23, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, June 23, 2022 | NON-FINAL ACTION E-MAILED |
| Thursday, June 23, 2022 | NON-FINAL ACTION WRITTEN |
| Tuesday, June 21, 2022 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Wednesday, March 16, 2022 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, March 16, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, March 16, 2022 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Wednesday, December 1, 2021 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
| Tuesday, June 1, 2021 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Tuesday, June 1, 2021 | LETTER OF SUSPENSION E-MAILED |
| Tuesday, June 1, 2021 | SUSPENSION LETTER WRITTEN |
| Tuesday, June 1, 2021 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, June 1, 2021 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, June 1, 2021 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, June 1, 2021 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, May 28, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, May 27, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, May 27, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, December 4, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, December 4, 2020 | NON-FINAL ACTION E-MAILED |
| Friday, December 4, 2020 | NON-FINAL ACTION WRITTEN |
| Wednesday, November 4, 2020 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Saturday, October 24, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Saturday, October 24, 2020 | NON-FINAL ACTION E-MAILED |
| Saturday, October 24, 2020 | NON-FINAL ACTION WRITTEN |
| Wednesday, October 21, 2020 | ASSIGNED TO EXAMINER |
| Thursday, August 6, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, July 14, 2020 | NEW APPLICATION ENTERED |